13 August 2025
13 August 2025
Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.
The ketamine product is the first to be approved in an analgesic setting by the US regulator.
Brinsupri becomes the first bronchiectasis therapy while ushering in a new class of DPP1 inhibitors.
South Korea鈥檚 pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.
Construction of the new API facility will commence in autumn 2025.
Over its lifetime, the partnership could yield $453m in total payments to Anji.
Celea Therapeutics, the latest spinoff created by PureTech, was created to progress the latter鈥檚 lead IPF programme, deupirfenidone.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
